Abstract 132P
Background
To perform competing risk analysis and evaluate cancer- and noncancer-specific mortality in patients with gastric cancer after radical surgery.
Methods
A total of 5051 patients from our department (as training set) and a total of 7123 patients from the Surveillance, Epidemiology, and End Results (SEER) database (as validation set) were enrolled in the study. The cumulative incidence of cancer and noncancer-specific mortality was determined by univariate and multivariate competing risk analysis.
Results
The five-year cancer- and noncancer-specific cumulative incidence of death (CID) in the training set were 36.9% and 2.5%, respectively, which were significantly lower than that in the validation set (48.2% and 8.6%, respectively). Multivariable analysis showed that age, tumor site, tumor size and pTNM stage were independent predictors of gastric cancer-specific mortality and overall survival, whereas age was an independent predictor of gastric noncancer-specific mortality. Noncancer–specific CID surpassed cancer-specific CID for pTNM stage I patients after approximately 8 years of surgery, but never for stage II and III patients. Moreover, for stage I patients, the time point when noncancer–specific CID surpassed cancer-specific CID become earlier as age increasing, with only 3.5 years after surgery for patients more than 74 years of age.
Conclusions
Age is an independent predictor of gastric cancer- and noncancer specific mortality and overall survival for patients after radical surgery. For patients with stage I gastric cancer, noncancer-specific mortality is a significant competing event, with an increasing impact as age increases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session